ATE284711T1 - Heilmittel und/oder prophylactische mittel zur behandlung von nervensystem-störungen - Google Patents
Heilmittel und/oder prophylactische mittel zur behandlung von nervensystem-störungenInfo
- Publication number
- ATE284711T1 ATE284711T1 AT00987648T AT00987648T ATE284711T1 AT E284711 T1 ATE284711 T1 AT E284711T1 AT 00987648 T AT00987648 T AT 00987648T AT 00987648 T AT00987648 T AT 00987648T AT E284711 T1 ATE284711 T1 AT E284711T1
- Authority
- AT
- Austria
- Prior art keywords
- calcium
- nervous system
- system disorders
- medicinal
- treatment
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title abstract 2
- 230000000069 prophylactic effect Effects 0.000 title 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 abstract 2
- 229910001424 calcium ion Inorganic materials 0.000 abstract 2
- 230000002107 myocardial effect Effects 0.000 abstract 2
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 abstract 2
- QTPMASWOWMYLBP-UHFFFAOYSA-N 2-[4-[(3,4-dimethoxyphenyl)methyl]piperazin-1-yl]-5-propylbenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC(CCC)=CC=C1N1CCN(CC=2C=C(OC)C(OC)=CC=2)CC1 QTPMASWOWMYLBP-UHFFFAOYSA-N 0.000 abstract 1
- 229940121819 ATPase inhibitor Drugs 0.000 abstract 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 abstract 1
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract 1
- 238000009825 accumulation Methods 0.000 abstract 1
- 239000000362 adenosine triphosphatase inhibitor Substances 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000000648 anti-parkinson Effects 0.000 abstract 1
- 239000000939 antiparkinson agent Substances 0.000 abstract 1
- 229910052791 calcium Inorganic materials 0.000 abstract 1
- 239000011575 calcium Substances 0.000 abstract 1
- 239000000480 calcium channel blocker Substances 0.000 abstract 1
- 239000000801 calcium channel stimulating agent Substances 0.000 abstract 1
- 230000001966 cerebroprotective effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000011597 hartley guinea pig Methods 0.000 abstract 1
- 230000002439 hemostatic effect Effects 0.000 abstract 1
- 238000010348 incorporation Methods 0.000 abstract 1
- 230000003834 intracellular effect Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 230000000324 neuroprotective effect Effects 0.000 abstract 1
- 230000001777 nootropic effect Effects 0.000 abstract 1
- 238000005086 pumping Methods 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP36268099 | 1999-12-21 | ||
| JP2000065272 | 2000-03-09 | ||
| PCT/JP2000/009024 WO2001045739A1 (en) | 1999-12-21 | 2000-12-20 | Remedies and/or preventives for nervous system disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE284711T1 true ATE284711T1 (de) | 2005-01-15 |
Family
ID=26581413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00987648T ATE284711T1 (de) | 1999-12-21 | 2000-12-20 | Heilmittel und/oder prophylactische mittel zur behandlung von nervensystem-störungen |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7652017B2 (de) |
| EP (1) | EP1249245B1 (de) |
| KR (1) | KR100740477B1 (de) |
| CN (1) | CN100486574C (de) |
| AT (1) | ATE284711T1 (de) |
| AU (1) | AU2398001A (de) |
| CA (1) | CA2394633A1 (de) |
| DE (1) | DE60016803T2 (de) |
| ES (1) | ES2233493T3 (de) |
| WO (1) | WO2001045739A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1374868A4 (de) * | 2001-03-13 | 2005-03-09 | Mitsubishi Pharma Corp | Mittel zur behandlung und/oder verhütung von diabetischen ischämischen herzerkrankungen |
| JP2004538292A (ja) * | 2001-07-25 | 2004-12-24 | 三菱ウェルファーマ株式会社 | ナトリウム・カルシウム交換系を阻害する医薬 |
| US20050004139A1 (en) * | 2001-07-30 | 2005-01-06 | Takeshi Inamori | Pharmaceutical preparations containing aminobenzene-sulfonic acid derivatives as the active ingredient |
| JPWO2004022545A1 (ja) * | 2002-09-06 | 2005-12-22 | 三菱ウェルファーマ株式会社 | 移植臓器保護剤 |
| WO2004069275A1 (ja) * | 2003-02-04 | 2004-08-19 | Mitsubishi Pharma Corporation | 眼科用剤 |
| US20060142395A1 (en) * | 2003-05-06 | 2006-06-29 | University Of North Texas Health Science Center | Modulation of intracellular calcium signaling by N-acylethanolamines |
| US20070129441A1 (en) * | 2003-05-06 | 2007-06-07 | University Of North Texas Health Science Center At Fort Worth | Protection of cells from adverse external or intrinsic effects, cellular degeneration and death by n-acylethanolamines |
| AU2021239199A1 (en) * | 2020-03-19 | 2022-10-06 | Sea6 Energy Pvt. Ltd. | Composite, process for preparing the composite, and implementation thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0233728A1 (de) * | 1986-02-11 | 1987-08-26 | Takeda Chemical Industries, Ltd. | 1,4-Benzoxazin-Derivate, ihre Herstellung und Verwendung |
| US5053409A (en) * | 1989-03-27 | 1991-10-01 | Mitsubishi Kasei Corporation | Aminobenzenesulfonic acid derivatives |
| JPH0686438B2 (ja) | 1989-03-27 | 1994-11-02 | 三菱化成株式会社 | アミノベンゼンスルホン酸誘導体 |
| GB9226111D0 (en) * | 1992-12-15 | 1993-02-10 | Smithkline Beecham Plc | Madicaments |
| CA2152394A1 (en) * | 1992-12-22 | 1994-07-07 | Ronald Joseph King | Piperidine derivatives as calcium channel antagonists |
| CA2192731C (en) * | 1995-12-15 | 2005-09-27 | Chika Yamazaki | Monohydrates of aminobenzenesulfonic acid derivatives and method for preparing thereof |
-
2000
- 2000-12-20 ES ES00987648T patent/ES2233493T3/es not_active Expired - Lifetime
- 2000-12-20 CA CA002394633A patent/CA2394633A1/en not_active Abandoned
- 2000-12-20 WO PCT/JP2000/009024 patent/WO2001045739A1/ja not_active Ceased
- 2000-12-20 DE DE60016803T patent/DE60016803T2/de not_active Expired - Lifetime
- 2000-12-20 AU AU23980/01A patent/AU2398001A/en not_active Abandoned
- 2000-12-20 EP EP00987648A patent/EP1249245B1/de not_active Expired - Lifetime
- 2000-12-20 CN CNB008189773A patent/CN100486574C/zh not_active Expired - Fee Related
- 2000-12-20 US US10/168,342 patent/US7652017B2/en not_active Expired - Fee Related
- 2000-12-20 AT AT00987648T patent/ATE284711T1/de not_active IP Right Cessation
- 2000-12-20 KR KR1020027008074A patent/KR100740477B1/ko not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR100740477B1 (ko) | 2007-07-19 |
| CN1434724A (zh) | 2003-08-06 |
| EP1249245B1 (de) | 2004-12-15 |
| ES2233493T3 (es) | 2005-06-16 |
| CA2394633A1 (en) | 2001-06-28 |
| CN100486574C (zh) | 2009-05-13 |
| US20030114427A1 (en) | 2003-06-19 |
| EP1249245A4 (de) | 2003-06-11 |
| WO2001045739A1 (en) | 2001-06-28 |
| US7652017B2 (en) | 2010-01-26 |
| EP1249245A1 (de) | 2002-10-16 |
| DE60016803T2 (de) | 2005-12-29 |
| KR20020063254A (ko) | 2002-08-01 |
| DE60016803D1 (de) | 2005-01-20 |
| AU2398001A (en) | 2001-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0005251D0 (en) | Therapeutic compounds | |
| DE60022916D1 (de) | Reboxetin zur Behandlung von peripheren Neuropathien | |
| ATE218854T1 (de) | Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin- abhängigen protein kinase | |
| ATE316785T1 (de) | Jak-3 hemmer zur behandlung von allergischen störungen | |
| DE60114580D1 (de) | Verwendung von cyanochinolinen zur behandlung oder inhibierung von dickdarmpolypen | |
| DE60023128D1 (de) | Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen | |
| DE60021266D1 (de) | Verwendungen von zusammensetzungen zur behandlung oder vermeidung von schlafstörungen mit sehr niedrigdosierten cyclobenzaprine | |
| DE69926385D1 (de) | Behandlung von geweben | |
| ATE350030T1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
| BG106118A (en) | Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit | |
| DE69935853D1 (de) | Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten | |
| ATE284711T1 (de) | Heilmittel und/oder prophylactische mittel zur behandlung von nervensystem-störungen | |
| ATE214272T1 (de) | Topische verwendung von kappa- opioidrezeptoragonisten zur behandlung von augenschmerz | |
| ATE332705T1 (de) | Verwendung von in der mittlere oder späte follikuläre phase verabreichte lh zur behandlung von anovulatorischen frauen | |
| ATE234617T1 (de) | Verwendung des saredutant und seiner pharmazeutisch akzeptablen salze zur behandlung von schwere depression | |
| DE69925578D1 (de) | Pharmazeutische zusammenstellung zur vorbeugung und behandlung von mit zellkrankheiten des augenhintergrundes zusammenhängenden krankheiten | |
| DE60036122D1 (de) | Verwendung von eplerenon zur behandlung von restenose | |
| BR0007686A (pt) | Uso de antagonistas receptores da angiotensina ii para tratar enfartação miocárdia aguda | |
| DK1152757T3 (da) | MMP-inhibitorer i bindevævsblödhed | |
| ATE294584T1 (de) | Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz | |
| GB9929497D0 (en) | Improved amino acid mixtures for the treatment and/or management of certain diseases | |
| ATE278401T1 (de) | Verwendung von riluzol zur behandlung von akustischen traumazuständen | |
| WO2002024727A3 (en) | New inhibitors of iapp fibril formation and uses thereof | |
| DE69906701D1 (de) | Topische verwendung von loperamid zur behandlung mikrobieller infektionen | |
| PT1212119E (pt) | Utilizacao de ciamemazina no tratamento do desmame subito de benzodiazepinas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |